The research, led by Ci Li and colleagues in the hospital’s Department of Clinical Laboratory, analyzed records from 1,383 hospitalized neonates who were divided into two groups: 935 infants with pneumonia alone and 448 infants whose pneumonia was complicated by sepsis. The investigators collected clinical and laboratory data at the time of admission, including C-reactive protein, neutrophil count, and lymphocyte count, and used these values to calculate the IBI for each infant. The design was retrospective, meaning the researchers worked backward from existing medical records rather than following patients forward in real time, but the large sample size gives the findings considerable statistical weight.

The inflammatory burden index is best understood as a mathematical synthesis of two dimensions of a patient’s immune state. C-reactive protein, an acute-phase protein produced by the liver, rises rapidly when inflammation flares anywhere in the body, while the balance between neutrophils and lymphocytes in the circulating blood reflects how the innate and adaptive arms of the immune system are responding to an insult. By integrating these measurements into a single index, the IBI attempts to capture both the intensity of the inflammatory response and the immune function of the patient in one number. In adults, similar composite indices have gained traction because no single biomarker reliably separates localized infection from systemic disease; the neonatal population presents an even harder problem, since newborns have immature immune systems and their inflammatory markers behave differently from those of older children and adults.

When the researchers compared the two groups, the difference in IBI values was striking. Neonates whose pneumonia was complicated by sepsis had significantly higher IBI levels than those with pneumonia alone, a difference that held up at the stringent threshold of P less than 0.001. In practical terms, this means that the probability of seeing such a large gap between the groups by chance alone is vanishingly small, lending strong statistical support to the idea that the index genuinely tracks the transition from localized lung infection to systemic inflammatory involvement.

A critical question for any biomarker study is whether the marker is merely riding along with other known risk factors or carries independent diagnostic information. To address this, the team performed multivariable logistic regression analysis, a statistical technique that estimates the effect of one variable while mathematically holding a panel of other clinical covariates constant. After adjusting for these potential confounders, a higher IBI remained independently associated with an increased prevalence of sepsis among the study infants. This independence matters because it suggests the index is not simply a proxy for gestational age, illness severity, or other factors that already alert clinicians to trouble, but is contributing diagnostic signal of its own.

The researchers then turned to receiver operating characteristic curve analysis, the standard method for quantifying how well a diagnostic test discriminates between two conditions. An ROC curve plots true-positive rate against false-positive rate across all possible cutoff values of the test, and the area under the curve, or AUC, summarizes overall discriminatory power: an AUC of 0.5 indicates performance no better than a coin flip, while 1.0 indicates perfect classification. The IBI achieved an AUC of 0.76, with a 95 percent confidence interval of 0.73 to 0.79 and a P value below 0.001. In the conventional vocabulary of diagnostic medicine, an AUC in this range is generally described as fair to good, meaning the index discriminates between the two patient groups meaningfully better than chance, though not with the near-perfect separation that would allow it to stand alone as a definitive test.

That level of performance, the authors argue, is precisely what makes the IBI suitable as an adjunctive tool rather than a replacement for clinical judgment. Neonatal sepsis is notoriously difficult to confirm quickly. Blood cultures, the traditional gold standard, take days to yield results and can be negative even in genuinely septic infants, particularly if the mother received antibiotics before delivery. Meanwhile, the decision to escalate care, broaden antimicrobial coverage, or transfer an infant to a higher level of support cannot wait for culture results. A non-invasive marker calculable from blood samples already drawn on admission, as the IBI is, could therefore serve as an early warning signal that prompts closer monitoring or more aggressive intervention while definitive results are pending.

The study’s strengths include its substantial cohort and the rigor of its statistical approach, but several caveats deserve attention. Because the analysis was retrospective and conducted at a single institution, the findings will need validation in prospective studies and in hospitals serving different populations before the IBI can be recommended for widespread clinical use. The study was conducted in strict adherence to the Declaration of Helsinki and received formal approval from the Institutional Review Board at the Children’s Hospital Affiliated to Zhengzhou University, with a waiver of informed consent granted because of the retrospective design. The work was supported by the Medical Science and Technology Project of Henan Province, and the authors declare no competing interests. The article was published open access on 12 October 2026 under a Creative Commons license, making the full data and methods available for scrutiny by other research groups.

Beyond the immediate clinical question, the study contributes to a broader shift in how infection medicine thinks about biomarkers. Rather than chasing a single perfect test, researchers increasingly combine several imperfect measurements into composite scores that outperform any individual component. The IBI follows this logic, and its reported performance in newborns suggests that the approach can be adapted to populations whose physiology complicates the interpretation of standard inflammatory markers. If future prospective studies confirm these results, the index could be incorporated into admission protocols for infants with respiratory infections, helping clinicians stratify risk at the earliest possible moment.

For now, the message for clinicians and researchers is one of cautious optimism. The inflammatory burden index offers a simple, non-invasive way to quantify the inflammatory storm that distinguishes sepsis from uncomplicated pneumonia in neonates, achieving good discrimination in a large real-world cohort. It is not a crystal ball, and an AUC of 0.76 leaves room for error at the individual level, but as part of a layered diagnostic strategy alongside cultures, clinical scoring systems, and experienced bedside assessment, it may help close the dangerous gap between the onset of sepsis and its recognition. In a field where hours can determine outcomes, that gap is exactly where better tools are needed most.

Subject of Research: Diagnostic utility of the inflammatory burden index for distinguishing neonatal pneumonia with sepsis from uncomplicated pneumonia

Article Title: Clinical utility of the inflammatory burden index in differentiating neonatal pneumonia from pneumonia complicated by sepsis

Article References: Li, C., Gao, K., Yang, L., Fang, P., Zhu, Z., Jiang, S., Li, T., & Yang, J. (2026). Clinical utility of the inflammatory burden index in differentiating neonatal pneumonia from pneumonia complicated by sepsis. BMC Infectious Diseases. https://doi.org/10.1186/s12879-026-14624-5

Image Credits: AI Generated

DOI: 10.1186/s12879-026-14624-5

Keywords: inflammatory burden index, neonatal sepsis, neonatal pneumonia, biomarkers, C-reactive protein, neutrophil count, lymphocyte count, ROC analysis, diagnostic accuracy, neonatology, BMC Infectious Diseases, retrospective study